Stefania Basili, Roberto Carnevale, Cristina Nocella, Simona Bartimoccia, Valeria Raparelli, Giovanni Talerico, Lucia Stefanini, Giulio F. Romiti, Francesco Perticone, Gino R. Corazza, Fabio Piscaglia, Antonello Pietrangelo, Francesco Violi, PRO‐LIVER Collaborators – 2 March 2019 – We analyzed whether serum albumin is independently associated with portal vein thrombosis (PVT) in liver cirrhosis (LC) and if a biologic plausibility exists. This study was divided into three parts.

Christopher J. Danford, Ghideon Ezaz – 1 March 2019

1 March 2019

Peng Tang, Heng Boon Low, Chin Wen Png, Federico Torta, Jaspal Kaur Kumar, Hwee Ying Lim, Yi Zhou, Henry Yang, Veronique Angeli, Asim Shabbir, E. Shyong Tai, Richard A. Flavell, Chen Dong, Markus R. Wenk, Dan Yock Yang, Yongliang Zhang – 1 March 2019 – Nonalcoholic fatty liver disease is currently the most common liver disease and is a leading cause of liver‐related morbidity and mortality. However, its pathogenesis remains largely unclear.

Naoko Ohtani, Norifumi Kawada – 1 March 2019 – The gut and the liver are anatomically and physiologically connected, and this “gut–liver axis” exerts various influences on liver pathology. The gut microbiota consists of various microorganisms that normally coexist in the human gut and have a role of maintaining the homeostasis of the host. However, once homeostasis is disturbed, metabolites and components derived from the gut microbiota translocate to the liver and induce pathologic effects in the liver.

Fei Wang, Jing Wang, Yaru Li, Jing Yuan, Ping Yao, Sheng Wei, Huan Guo, Xiaomin Zhang, Handong Yang, Tangchun Wu, Meian He – 1 March 2019

Aaron G. Lim, Adam Trickey, Peter Vickerman – 1 March 2019

Zhen Huang, Lei‐Ming Wu, Jie‐Lei Zhang, Abdelkarim Sabri, Shou‐Jun Wang, Gui‐Jun Qin, Chang‐Qing Guo, Hong‐Tao Wen, Bin‐Bin Du, Dian‐Hong Zhang, Ling‐Yao Kong, Xin‐Yu Tian, Rui Yao, Ya‐Peng Li, Cui Liang, Peng‐Cheng Li, Zheng Wang, Jin‐Yan Guo, Ling Li, Jian‐Zeng Dong, Yan‐Zhou Zhang – 1 March 2019 – Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide. Due to the growing economic burden of NAFLD on public health, it has become an emergent target for clinical intervention.

Yuri L. Boteon, Joseph Attard, Amanda P. C. S. Boteon, Lorraine Wallace, Gary Reynolds, Stefan Hubscher, Darius F. Mirza, Hynek Mergental, Ricky H. Bhogal, Simon C. Afford – 28 February 2019 – Strategies to increase the use of steatotic donor livers are required to tackle the mortality on the transplant waiting list. We aimed to test the efficacy of pharmacological enhancement of the lipid metabolism of human livers during ex situ normothermic machine perfusion to promote defatting and improve the functional recovery of the organs.

Kristopher P. Croome, David D. Lee, C. Burcin Taner – 28 February 2019 – The frequency at which steatotic deceased donor liver grafts are encountered will likely continue to increase. Utilization of liver grafts with moderate‐to‐severe steatosis for liver transplantation (LT) has been previously shown to be associated with increased rates of primary nonfunction and decreased recipient survival. In order to better inform clinical decision making and guide future research, critical evaluation of the literature on donor liver steatosis and posttransplantation outcome is needed.